GRACELL BIOTECHNOLOGIES-ADR (GRCL)
US38406L1035 - ADR
Gracell Biotechnologies Acquisition Completed
Gracell Biotechnologies Acquisition Completed
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, Nasdaq:...
亘喜生物宣布正式并入阿斯利康集团
中国江苏苏州、上海和美国加利福尼亚州圣迭戈, Feb. 22, 2024 (GLOBE NEWSWIRE) -- 亘喜生物科技集团（纳斯达克股票代码：GRCL；简称“亘喜生物” 或“公司”）...
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
亘喜生物宣布公司股东正式投票表决通过了与阿斯利康的并购协议
中国江苏苏州、上海和美国加利福尼亚州圣迭戈, Feb. 20, 2024 (GLOBE NEWSWIRE) -- 亘喜生物科技集团（纳斯达克股票代码：GRCL；简称“亘喜生物” 或“公司”）...
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ:...
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Further expands clinical development of FasTCAR-T GC012F in multiple myeloma amid ongoing U.S. trial evaluating therapy for treatment of relapsed/refractory multiple myeloma
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Further expands clinical development of FasTCAR-T GC012F in multiple myeloma amid ongoing U.S. trial evaluating therapy for treatment of...
亘喜生物宣布FasTCAR-T GC012F早线治疗多发性骨髓瘤的1期新药临床试验（IND）申请获美国FDA批准
继已开展的复发/难治性多发性骨髓瘤（RRMM）临床试验，在美国进一步拓展FasTCAR-T GC012F针对多发性骨髓瘤适应症的临床开发...
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates AMAM, AXNX, HARP, GRCL
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates GRCL, RYZB, CPE, BRBS
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Kuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RYZB, KRTX, GRCL
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
The major indexes boast big annual gains with the Dow at record highs.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GRCL, RYZB, BRBS
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
GRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to Shareholders
AstraZeneca to Buy Cancer Drug Developer for Up to $1.2 Billion
AstraZeneca Plc agreed to acquire Chinese cell therapy developer Gracell Biotechnologies Inc. for as much as $1.2 billion as the British drug giant bolsters its bets on medical innovation in the world’s second-biggest economy.